{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '4.4 TARGET ACCRUAL AND STUDY DURATION', 'A maximum of 114 participants at 3 sites, including RPCI, will be enrolled. Accrual is expected', 'to take up to 4 years. Each participant is expected to be on the study for two years and will be', 'followed according to NCCN guidelines.', '5', 'PARTICIPANT SELECTION', 'The treating physician or his designee at each network site will determine eligibility.', '5.1', 'INCLUSION CRITERIA', 'To be included in this study, participants must meet the following criteria:', '1. Age > 18 years of age.', '2. Have an ECOG Performance Status of 2. Refer to Appendix D.', '3. Participants with previously untreated T1/T2 NO squamous cell carcinoma of the oral', 'cavity with or without extension to the oropharynx.', '4. Histologically confirmed squamous cell carcinoma of the target tumor(s).', '5. Tumor thickness is 4 mm or less (measured clinically and/or by CT or MRI scan).', '6. CT or MRI of the neck to confirm staging.', '7. Tumor accessible for unrestricted illumination for photodynamic Therapy (PDT)', '(accessibility as determined by the physician).', '8. Life expectancy of at least 12 months in the judgment of the physician.', '9. Participants of child-bearing potential must agree to use adequate contraceptive methods', '(e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for', 'the duration of study participation. Should a woman become pregnant or suspect she is', 'pregnant while she is participating in this study, she should inform her treating physician', 'immediately.', '10. Participant or legal representative must understand the investigational nature of this study', 'and sign an Institutional Review Board approved written informed consent form prior to', 'receiving any study related procedure.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 22 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '5.2', 'EXCLUSION CRITERIA', 'Participants will be excluded from this study for the following:', '1. Those who have had chemotherapy or radiotherapy or targeted agents within 4 weeks', '(6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have', 'not recovered from adverse events due to agents administered more than 4 weeks earlier.', '2. Those with known brain metastases should be excluded from this clinical trial because of', 'their poor prognosis and because they often develop progressive neurologic dysfunction', 'that would confound the evaluation of neurologic and other adverse events.', '3. Those with porphyria or with known hypersensitivity to porphyrins or porphyrin-like', 'compounds.', '4. WBC < 4,000.', '5. Those with impaired renal and/or hepatic function (total serum bilirubin >2 mg/dL, serum', 'creatinine > 2 mg/dL, alkaline phosphatase (hepatic) or SGOT > 3 times the upper normal', 'limit.', '6. Diagnostic biopsy reveals perineural invasion (PNI) and/or lymphovascular invasion', '(LVI).', '7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,', 'symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or', 'psychiatric illness/social situations that would limit compliance with study requirements.', '8. Nodal disease as detected by clinical exam or CT.', '9. Pregnant or nursing females.', '10. Unwilling or unable to follow protocol requirements.', \"11. Any condition which in the Investigator's opinion deems the participant an unsuitable\", 'candidate to receive study drug.', '12. Received an investigational agent within 30 days prior to enrollment.', '13. Trismus or compromised airway.', '14. Previous treatment in the target tumor area.', '5.3 INCLUSION OF WOMEN AND MINORITIES', 'Both men and women and members of all races and ethnic groups are eligible for this study.', 'For Network Sites, refer to Appendix A for site specific instructions.', '6', 'INVESTIGATIONAL PRODUCTS', '6.1', 'ACTIVE SUBSTANCE AND SOURCE', 'The drug (photosensitizer) to be used in this study is 2-[1-hexyloxyethyl]-2-Devinyl', 'pyropheophorbide-a (HPPH).', 'The HPPH is formulated for injection as follows:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 23 of 64']\n\n###\n\n", "completion": "END"}